Kevin C. Zorn, MD, FRCSC, FACS, outlines notable advances in the management of benign prostatic hyperplasia over the past year. In a recent interview with Urology Times®, Kevin C. Zorn, MD, FRCSC, ...
The PROSTOX ultra test predicts late genitourinary toxicity risks in localized prostate cancer patients undergoing stereotactic body radiotherapy. Genomic testing aids in refining treatment intensity ...
LithoVue Elite system's real-time IRP monitoring may enhance flexible ureteroscopy for larger stones, offering data-driven pressure management. CVAC 2.0 ureteroscope demonstrates safety and efficacy ...
The ProVee Urethral Expander System met safety and effectiveness endpoints in a pivotal phase 3 study, leading to its approval for BPH treatment. Rezūm Water Vapor Therapy received FDA approval for ...
"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...
The expert faculty analyze the recently presented ALBAN trial, a phase 3 study evaluating atezolizumab in combination with intravesical BCG versus BCG alone for BCG-naïve, high-risk non–muscle ...
In this opening segment, the discussion focuses on the rapid evolution of kidney stone surgery and how suction has transitioned from an aspirational idea to a core component of modern ureteroscopy.
Experts recommend removing unsupported prostate cancer warnings from TRT labels and aligning indications with professional guidelines. Testosterone's Schedule III classification creates barriers to ...
Mohit Khera, MD, MBA, MPH, recaps key takeaways from an FDA expert panel discussion on testosterone replacement therapy for men. In a recent interview with Urology Times®, Mohit Khera, MD, MBA, MPH, ...
The ProVee System received FDA approval for treating BPH, offering a safe and effective procedure for symptom relief and quality of life improvement. The ProVIDE study showed significant improvement ...
Gepotidacin is now approved for treating uncomplicated urogenital gonorrhea in patients 12 years and older, expanding its previous approval for urinary tract infections. The EAGLE-1 trial showed ...
NDV-01 showed a 92% complete response rate at any time point in high-risk NMIBC patients. The treatment is designed for easy in-office administration, requiring no anesthesia or specialized equipment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback